CN102775429A - 不饱和去甲基斑蝥酸银配聚物的制备和用途 - Google Patents
不饱和去甲基斑蝥酸银配聚物的制备和用途 Download PDFInfo
- Publication number
- CN102775429A CN102775429A CN2012102831208A CN201210283120A CN102775429A CN 102775429 A CN102775429 A CN 102775429A CN 2012102831208 A CN2012102831208 A CN 2012102831208A CN 201210283120 A CN201210283120 A CN 201210283120A CN 102775429 A CN102775429 A CN 102775429A
- Authority
- CN
- China
- Prior art keywords
- compound
- application
- alkene
- heptane
- demethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 9
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 7
- 239000004332 silver Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 title abstract 2
- 230000017858 demethylation Effects 0.000 title abstract 2
- 238000010520 demethylation reaction Methods 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000013078 crystal Substances 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 3
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 14
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- -1 unsaturated demethyl Cantharidic acid Chemical compound 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ZZDBMDNRQQDSKG-UHFFFAOYSA-N methyl 5-bromo-1-benzofuran-2-carboxylate Chemical class BrC1=CC=C2OC(C(=O)OC)=CC2=C1 ZZDBMDNRQQDSKG-UHFFFAOYSA-N 0.000 claims description 6
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical class C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 5
- 229930008399 cantharidic acid Natural products 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052697 platinum Inorganic materials 0.000 abstract description 3
- 238000002425 crystallisation Methods 0.000 abstract 2
- 230000008025 crystallization Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- 231100000086 high toxicity Toxicity 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 206010065553 Bone marrow failure Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940095758 cantharidin Drugs 0.000 description 3
- 229930008397 cantharidin Natural products 0.000 description 3
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 101710134784 Agnoprotein Proteins 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- JLYVRXJEQTZZBE-UHFFFAOYSA-N ctk1c6083 Chemical compound NP(N)(N)=S JLYVRXJEQTZZBE-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种不饱和去甲基斑蝥酸银配位聚合物的合成方法和用途，该物质外观呈无色块状晶体，分子式{[Ag(C8H7O5)]·H2O}n，n为聚合度，结晶水数量可变。化学名为：聚[[[μ3-(5,6-η):κO2:κO2-(±)-(1S，2S，3R，4R)–3–羧基–7-氧代二环-[2.2.1]庚烷-5-烯-2–羧负离子]银(I)]一水合物]，结构如下（结晶水数量可变）：
Description
技术领域
本发明涉及药物无机化学领域，具体涉及一类含银的不饱和去甲基斑蝥酸配聚物的制备及用途。
背景技术
金属元素在生命中扮演了重要的角色。生物体中的金属大都以阳离子形式存在，因为只有阳离子才能在体液中溶解。金属阳离子是缺电子的，而大多数生物分子都是富电子的，如蛋白质、DNA等，因此，带相反电荷的金属离子与生物分子有结合或相互作用的倾向。这种类似的倾向也存在于金属离子和一些对生命有重要价值的小分子之间。金属离子中值得注意的是银，其配合物作为一类近年来被广泛研究的潜在药物，显示出诱人的应用前景，主要是因为它们对一些癌细胞表现出强烈毒性的同时，对正常细胞的毒性很小[W. J. Youngs,A. R. Knapp,P. O. Wagers, C. A. Tessier, Dalton Trans. 41 (2012) 327–336.]，在这方面优于金属铂。
去甲斑蝥素就是把2、3位上的两个甲基去掉，其临床毒性远小于斑蝥素，仍有很好抗肿瘤效果，从二十世纪八十年代开始在中国用于人类癌症尤其是肝癌的临床治疗[Kok, S. H.; Cheng, S. J.; Hong, C. Y.; Lee, J. J.; Lin, S. K.; Kuo, Y. S.; Chiang, C. P.; Kuo, M. Y., Cancer Lett. 2005, 217, 43–52.]。体外实验证实，去甲斑蝥素对多种癌细胞[如A2780 (Human ovarian carcinoma), G401 (human kidney carcinoma), HT29 (human colorectal carcinoma), H460 (human lung carcinoma), L1210 (murine leukemia)]的半数生长抑制浓度（GI50，the concentration that induces 50% growth inhibition compared with untreated control cells.）均略大于斑蝥素[Matthew E. Hart, A. Richard Chamberlin, Cecilia Walkom, Jennette A. Sakoff and Adam McCluskey, Bioorganic & Medicinal Chemistry Letters 14 (2004) 1969–1973.]。临床实验也证实了去甲斑蝥素的药用价值。Wang G. S.等人对285名一级肝癌（primary hepatoma）病人用去甲斑蝥素治疗，对照102名病人的传统化疗方法（如：5FU, hydroxycamptotherine, vincristine, thiophosphoramide and mitomycin），发现均可以延长病人的存活时间，从4.7-11.1个月不等，有17–30%的病人存活时间可以延长一年以上[Wang G. S., J. Ethnopharmacol, 1989, 26(2): 147.]。和用斑蝥素治疗的病人相比，用去甲斑蝥素治疗的病人不会出现骨髓抑制（myelosuppression）现象从而导致造血功能受到抑制，恰恰相反，去甲斑蝥素反而能刺激骨髓造血[Liu X-H, Balzsek I, Comisso M, Legras S, Marion S, Quittet P, Anjo A, Wang G-S, Eur J Cancer 31A(1995): 953–963.]。这种反常的刺激也是短暂的，大概持续一个星期左右，在良好的护理下，白细胞水平会恢复到正常值。一个有趣的现象是，在老鼠身上的实验证实，去甲斑蝥素能阻止环磷酰胺类化疗药物引起的骨髓抑制现象，即可以抵制由其他化疗药物引起的白血球减少的现象。
本课题组曾经首次合成过一种Ag+和不饱和去甲斑蝥素的配聚物，详细研究过其晶体结构[Wang Feng-Yan, Jiang Xue-Bing, Tan Xue-Jie, Xing Dian-Xiang, Acta Crystallographica C67 (2011), m218-m220.]。七个月后，重庆大学的龚云等人又详细研究了该化合物的电催化性质[Gong, Yun; Wu, Tao; Li, Jinghua; Lin, Jianhua.，Inorganic Chemistry Communications (2012), 19 39-42.]，并对合成方法作了一些改进。本发明在以上工作的基础上进一步改进了合成方法，并且研究了其体外抗肿瘤活性，发现该化合物在医药领域具有很好的应用前景。
发明内容
本发明的内容是合成了一种不饱和去甲基斑蝥酸银配位聚合物，外观呈无色块状晶体，分子式{[Ag(C8H7O5)]·H2O}n，n为聚合度，结晶水数量可变。化学名为：聚[[[μ3-(5,6-η):κO2:κO2 - (±) - (1S，2S，3R，4R) – 3 – 羧基 – 7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯- 2 – 羧负离子]银(I)] 一水合物]，结构如下（结晶水数量可变）：
1、合成方法：
配聚物{[Ag(C8H7O5)]·H2O}n合成方法上的特征在于：以去甲基不饱和斑蝥酸{即：7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯 - 2, 3 - 二羧酸}或去甲基不饱和斑蝥素{即：7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯 - 2,3-外型-二羧酸酐}和银离子为原料，在合适的溶剂中混合，自然挥发。步骤如下：
1）将配体去甲基不饱和斑蝥酸和AgNO3加入溶剂中，配成合适浓度的溶液，然后按一定比例混合，过滤后常温常压下自然挥发；
2）一段时间后可得到晶体状物，分离出即为产物；
优选的，配体去甲基不饱和斑蝥酸和AgNO3的摩尔比为：2∶1 ~ 1∶2；
优选的，所述溶剂选自：水，甲醇、乙醇。
2、体外抗肿瘤活性：
将处于对数期生长的A549肺癌细胞，用0.25%胰酶消化细胞，使其成为单细胞，用含10%胎牛血清的F12K培养液制成浓度为1.25×107个/L的单细胞悬液，将细胞接种于96孔培养板中，每孔200μL（每孔2.5×103个细胞）。将96孔细胞培养板置于CO2培养箱中，在37℃，5%CO2条件下，培养48h。
当孔内细胞长满（90%满即可）时，按实验分组加入不同剂量的配合物溶液（200μL/孔），使待测化合物的终浓度分别为5μM、10μM、30μM、50μM、100μM，每组设3个复孔，培养96h。
各个孔中分别加入20μL浓度为0.5g/L的MTT，继续培养4h，使MTT还原为甲瓒（Formazan）。吸出全部上清液后，每孔加入200μL的DMSO，震摇15min，使甲瓒充分溶解后，运用酶联免疫检测仪测定490nm处的吸光度（OD值）。然后按照下式进行计算：
细胞抑制率%=（对照组OD值 - 实验组OD值）/ 对照组OD值 ×100%
测试结果表明，配合物分子对肺癌细胞A549的IC50（药物的半数抑制浓度）为7.28μM。这表明配合物分子对肺癌细胞具有很好的抑制效果，与顺铂对A549肺癌细胞的抑制效果（IC50=7.0μM）相当。
具体实施方式
为了更好的理解本发明内容，下面通过几个具体实施例进一步说明本发明的技术方案。以下实施例并不限定本发明。
实施例1
将配好的配体去甲基不饱和斑蝥酸与硝酸银的0.01mol/L无水乙醇溶液，各取20mL，分别过滤后以1:1的摩尔比混合于烧杯内，常温下静置24-72小时，得到无色透明块状晶体，即为目标产物。
Claims (7)
1.一种不饱和去甲基斑蝥酸银配位聚合物，外观呈无色块状晶体，分子式{[Ag(C8H7O5)]·H2O}n，n为聚合度，结晶水数量可变，化学名为：聚[[[μ3-(5,6-η):κO2:κO2 - (±) - (1S，2S，3R，4R) – 3 – 羧基 – 7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯- 2 – 羧负离子]银(I)] 一水合物]，结构如下（结晶水数量可变）：
。
2.权利要求1所述的化合物的合成方法，其特征在于：以去甲基不饱和斑蝥素{即：7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯 - 2,3-外型-二羧酸酐}或去甲基不饱和斑蝥酸{即：7 - 氧代二环 - [2.2.1]庚烷 - 5 - 烯 - 2, 3 - 二羧酸}和银离子为原料。
3.如权利要求1所述的化合物的合成方法，其特征在于：所述溶剂选自：甲醇、乙酸乙酯、二氯甲烷、乙醇、乙腈、水。
4.如权利要求1所述的化合物的合成方法，其特征在于：反应一步完成，以自然挥发生成产物为主。
5.如权利要求1所述的化合物在制备预防和/或治疗肿瘤药物中的应用。
6.如权利要求5所述的应用，其特征在于：所述肿瘤为癌。
7.如权利要求6所述的应用，其特征在于：所述癌为肺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210283120.8A CN102775429B (zh) | 2012-08-10 | 不饱和去甲基斑蝥酸银配聚物的制备和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210283120.8A CN102775429B (zh) | 2012-08-10 | 不饱和去甲基斑蝥酸银配聚物的制备和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102775429A true CN102775429A (zh) | 2012-11-14 |
| CN102775429B CN102775429B (zh) | 2016-11-30 |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105601651A (zh) * | 2016-03-18 | 2016-05-25 | 齐鲁工业大学 | 三乙烯四胺基斑蝥酰亚胺二聚体衍生物的结构、制备和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500789A (zh) * | 2002-11-19 | 2004-06-02 | 北京大学 | 含去甲基斑蝥酸根(DCA)的铜(Ⅱ)、镓(Ⅲ)及稀土离子(Ln3+)混配配合物ML(DCA) |
| CN1686102A (zh) * | 2005-04-08 | 2005-10-26 | 中山大学 | 斑蝥素衍生物在制备抗肿瘤药物中的应用 |
| CN1861610A (zh) * | 2005-05-11 | 2006-11-15 | 武德柱 | 去甲斑蝥素－钕的合成 |
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500789A (zh) * | 2002-11-19 | 2004-06-02 | 北京大学 | 含去甲基斑蝥酸根(DCA)的铜(Ⅱ)、镓(Ⅲ)及稀土离子(Ln3+)混配配合物ML(DCA) |
| CN1686102A (zh) * | 2005-04-08 | 2005-10-26 | 中山大学 | 斑蝥素衍生物在制备抗肿瘤药物中的应用 |
| CN1861610A (zh) * | 2005-05-11 | 2006-11-15 | 武德柱 | 去甲斑蝥素－钕的合成 |
Non-Patent Citations (2)
| Title |
|---|
| 20120202: ""Unsymmetrical coordinated Ag(I)-olefin complex based on ...Synthesis, structure and electrocatalytical property"", 《INORGANIC CHEMISTRY COMMUNICATIONS》 * |
| F Y WANG等: ""A two-dimensional undulating AgI coordination polymer constructed of Ag-C and Ag-O bonds:poly[[[μ3-(5,6-η):κO2:κO2-(±)-(1S,2S,3R,"A two-dimensional undulating AgI coordination polymer constructed of Ag-C and Ag-O bonds:poly... monohydrate"", 《ACTA CRYSTALLOGRAPHICA SECTION C》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105601651A (zh) * | 2016-03-18 | 2016-05-25 | 齐鲁工业大学 | 三乙烯四胺基斑蝥酰亚胺二聚体衍生物的结构、制备和用途 |
| CN105601651B (zh) * | 2016-03-18 | 2017-11-28 | 齐鲁工业大学 | 三乙烯四胺基斑蝥酰亚胺二聚体衍生物的结构、制备和用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103450281B (zh) | 一种1-氮杂苯并蒽酮-铂(ii)配合物及其合成方法和应用 | |
| Cheng et al. | Synthesis, structure and antitumor studies of a novel decavanadate complex with a wavelike two-dimensional network | |
| CN103748080A (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂及其制造方法与应用 | |
| PT727430E (pt) | Complexos de platina | |
| Akkoç et al. | Protonated water-soluble N-heterocyclic carbene ruthenium (II) complexes: Synthesis, cytotoxic and DNA binding properties and molecular docking study | |
| WO2012155559A1 (zh) | 有机杂化四核铂配合物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN102627685A (zh) | 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途 | |
| CN112940059A (zh) | 一种糖基修饰的萘酰亚胺-多胺缀合物、其制备方法及应用 | |
| CN105481902B (zh) | 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物 | |
| CN107362166A (zh) | 四氢吡啶并[4,5‑]噻吩并[2,3‑]嘧啶‑4(3)‑酮类化合物在制药中的应用 | |
| CN104058946B (zh) | 具有抗肿瘤活性的大黄素过渡金属配合物、制备方法及其应用 | |
| CN102775429A (zh) | 不饱和去甲基斑蝥酸银配聚物的制备和用途 | |
| CN104151304B (zh) | 一种三唑类化合物 | |
| CN102775429B (zh) | 不饱和去甲基斑蝥酸银配聚物的制备和用途 | |
| CN102603805A (zh) | 具有抗肿瘤活性的铂（ii）配合物及其制备方法 | |
| CN110698383B (zh) | 苯偶酰腙-3-乙酰基吲哚的结构、合成及用途 | |
| CN103992394B (zh) | 一种人工合成的阳离子肽及其在制备抗肿瘤药物中的用途 | |
| Sun et al. | Synthesis and biological evaluation of platinum (II) complexes containing (1R, 2R)-N1-alkyl-1, 2-diaminocyclohexane and D-(+)-camphorate ligands | |
| CN104961752A (zh) | 一种双核铜(ii)–唑来膦酸配合物及应用 | |
| CN101239990A (zh) | N-（2，3，4，5，6-五羟基己基）-l-氨基酸合铂、其制备方法及应用 | |
| CN103980183B (zh) | 取代哌啶氨荒酸铋(ⅲ)配合物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN109692170A (zh) | 一种抗乳腺癌药物 | |
| CN104086597A (zh) | 以3-氧代-环丁烷-1,1-二羧酸根为配体的铂(ii)抗肿瘤化合物 | |
| CN113024450B (zh) | 一种二硫代甲酯钴(iii)配合物及其制备方法和应用 | |
| CN102659849B (zh) | 一种具有抗肿瘤活性的铂（ii）配合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 250353 University Road, Science Park, West New Town University, Ji'nan, Shandong Applicant after: Qilu University of Technology Address before: 250353 New Town University, Science Park, University Road, Shandong Light Industries College, Ji'nan, Shandong Applicant before: Shandong Institute of Light Industry |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG INSTITUTE OF LIGHT INDUSTRY TO: QILU UNIVERSITY OF TECHNOLOGY |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tan Xuejie Inventor after: Shi Yan Inventor after: Xing Dianxiang Inventor after: Liu Yun Inventor before: Tan Xuejie Inventor before: Xing Dianxiang Inventor before: Liu Yun |
|
| COR | Change of bibliographic data | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tan Xuejie Inventor after: Wang Chao Inventor after: Shi Yan Inventor after: Xing Dianxiang Inventor after: Liu Yun Inventor before: Tan Xuejie Inventor before: Shi Yan Inventor before: Xing Dianxiang Inventor before: Liu Yun |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20170810 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |